Latanoprostene (PF3187207; Latanoprostene BUNOD; LBN; BOL-303259-X; NCX116; Vesneo; Vyzulta) is a novel and potent nitric oxide (NO)-donating FP receptor (Prostaglandin F2α receptor) agonist with prostaglandin activity. It loweres intraocular pressure (IOP) more effectively than latanoprost in monkeys, dogs and rabbits. Latanoprostene was approved for use as an ophthalmic drug in the United States in 2017 for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It targets the trabecular meshwork directly.

纯度：≥98%

CAS：860005-21-6